Literature DB >> 15026200

Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.

Aeron C Hurt1, Ian G Barr, Gunter Hartel, Alan W Hampson.   

Abstract

Human influenza viruses isolated from Australasia (Australia and New Zealand) and South East Asia were analysed to determine their sensitivity to the NA inhibitor drugs, zanamivir and oseltamivir. A total of 532 strains isolated between 1998 and 2002 were tested using a fluorescence-based assay to measure the relative inhibition of NA activity over a range of drug concentrations. Based on median IC50 values, influenza A viruses (with neuraminidase subtypes N1 and N2) were more sensitive to both the NA inhibitors than were influenza B strains. Influenza A viruses with a N1 subtype and influenza B strains both demonstrated a greater sensitivity to zanamivir than to oseltamivir carboxylate, whereas influenza A strains with a N2 subtype were more susceptible to oseltamivir carboxylate. For each of the neuraminidase types, IC50 values for viruses from Australasia and South East Asia were found to be comparable. Based on the data prior to and following the licensing of the drugs into the respective regions, the use of the NA inhibitors did not appear to have a significant impact on the susceptibility of the viruses tested to zanamivir or oseltamivir carboxylate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026200     DOI: 10.1016/j.antiviral.2003.11.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  41 in total

1.  Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.

Authors:  Yasushi Suzuki; Reiko Saito; Isamu Sato; Hassan Zaraket; Makoto Nishikawa; Tsutomu Tamura; Clyde Dapat; Isolde Caperig-Dapat; Tatiana Baranovich; Takako Suzuki; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

Review 2.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

3.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 4.  Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

Authors:  Zhengtu Li; Li Li; Shuai Zhao; Jing Li; Hongxia Zhou; Yunhui Zhang; Zifeng Yang; Bing Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Genotyping assay for the identification of 2009-2010 pandemic and seasonal H1N1 influenza virus reassortants.

Authors:  M F Ducatez; S Sonnberg; R J Hall; M Peacey; J Ralston; R J Webby; Q S Huang
Journal:  J Virol Methods       Date:  2010-05-05       Impact factor: 2.014

6.  Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.

Authors:  Aeron C Hurt; Pina Iannello; Kim Jachno; Naomi Komadina; Alan W Hampson; Ian G Barr; Jennifer L McKimm-Breschkin
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

7.  Influenza outbreaks during World Youth Day 2008 mass gathering.

Authors:  Christopher C Blyth; Hong Foo; Sebastiaan J van Hal; Aeron C Hurt; Ian G Barr; Kenneth McPhie; Paul K Armstrong; William D Rawlinson; Vicky Sheppeard; Stephen Conaty; Michael Staff; Dominic E Dwyer
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

8.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

Authors:  Nadezhda E Yun; Nathaniel S Linde; Michele A Zacks; Ian G Barr; Aeron C Hurt; Jeanon N Smith; Natallia Dziuba; Michael R Holbrook; Lifang Zhang; John M Kilpatrick; C Shane Arnold; Slobodan Paessler
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

10.  Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa.

Authors:  Terry G Besselaar; Dhamari Naidoo; Amelia Buys; Vicky Gregory; Jo McAnerney; Jack M Manamela; Lucille Blumberg; Barry D Schoub
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.